Response to the study: ‘Syringe plunger contamination by hazardous drugs: A comparative study,’ by Stephen T Smith and Mark C Szlaczky1.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Works matching IS 10781552 AND DT 2014 AND VI 20 AND IP 5
Results: 14
1
2
Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
3
Response to the Editor.
- Published in:
- 2014
- By:
- Publication type:
- Letter to the Editor
4
Response to the study: ‘Syringe plunger contamination by hazardous drugs: A comparative study,’ by Stephen T Smith and Mark C Szlaczky1.
- Published in:
- 2014
- By:
- Publication type:
- Letter to the Editor
5
Syringe plunger contamination by hazardous drugs: A comparative study.
- Published in:
- Journal of Oncology Pharmacy Practice, 2014, v. 20, n. 5, p. 381, doi. 10.1177/1078155214526428
- By:
- Publication type:
- Article
6
First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: Cost-minimization analysis.
- Published in:
- Journal of Oncology Pharmacy Practice, 2014, v. 20, n. 5, p. 362, doi. 10.1177/1078155213508440
- By:
- Publication type:
- Article
7
Prognostic value of plasma levels of thrombomodulin and von Willebrand factor in Egyptian children with acute lymphoblastic leukemia.
- Published in:
- Journal of Oncology Pharmacy Practice, 2014, v. 20, n. 5, p. 356, doi. 10.1177/1078155213508439
- By:
- Publication type:
- Article
8
Authorising bortezomib treatment prior to reviewing haematology results: a step toward home administration.
- Published in:
- Journal of Oncology Pharmacy Practice, 2014, v. 20, n. 5, p. 351, doi. 10.1177/1078155213508438
- By:
- Publication type:
- Article
9
Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
- Published in:
- Journal of Oncology Pharmacy Practice, 2014, v. 20, n. 5, p. 341, doi. 10.1177/1078155213508437
- By:
- Publication type:
- Article
10
Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapy.
- Published in:
- Journal of Oncology Pharmacy Practice, 2014, v. 20, n. 5, p. 332, doi. 10.1177/1078155213507010
- By:
- Publication type:
- Article
11
A curious case of oxaliplatin-induced neurotoxicity: Recurrent, self-limiting dysarthria.
- Published in:
- Journal of Oncology Pharmacy Practice, 2014, v. 20, n. 5, p. 393, doi. 10.1177/1078155213506477
- By:
- Publication type:
- Article
12
Intraperitoneal chemotherapy: Rationale, applications, and limitations.
- Published in:
- Journal of Oncology Pharmacy Practice, 2014, v. 20, n. 5, p. 369, doi. 10.1177/1078155213506244
- By:
- Publication type:
- Article
13
Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis.
- Published in:
- Journal of Oncology Pharmacy Practice, 2014, v. 20, n. 5, p. 386, doi. 10.1177/1078155213504444
- By:
- Publication type:
- Article
14
Reducing the risk of harm from intravenous potassium: A multi-factorial approach in the haematology setting.
- Published in:
- Journal of Oncology Pharmacy Practice, 2014, v. 20, n. 5, p. 323, doi. 10.1177/1078155213504443
- By:
- Publication type:
- Article